Functional and Omics-Based Rationale for the Induction of BRCAness by Androgen Receptor Pathway Inhibitors to Sensitize Prostate Cancer to PARP Inhibition, Regardless of HRR Status

Researchers assessed poly (ADP‒ribose) polymerase (PARP) inhibitors alone and with androgen receptor pathway inhibitors in prostate cancer cell lines, metastatic patient-derived organoids, and LN-metastatic tissue slice cultures.